MAPKAPK3

MAP kinase-activated protein kinase 3

11,983 patent compounds predicted against MAPKAPK3, 8,271 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1663652	0.62	5/20
SCHEMBL12222	0.56	5/20
SCHEMBL1922328	0.55	5/20
SCHEMBL1663793	0.59	4/20
SCHEMBL1145076	0.57	4/20
SCHEMBL1663211	0.51	4/20
SCHEMBL695280	0.42	4/20
SCHEMBL760696	0.63	3/20
SCHEMBL760551	0.63	3/20
SCHEMBL1406065	0.61	3/20
SCHEMBL760046	0.56	3/20
SCHEMBL760538	0.55	3/20
SCHEMBL759930	0.54	3/20
SCHEMBL760758	0.54	3/20
SCHEMBL759017	0.53	3/20
SCHEMBL760360	0.53	3/20
SCHEMBL760344	0.53	3/20
SCHEMBL760492	0.52	3/20
SCHEMBL760000	0.51	3/20
SCHEMBL117222	0.51	3/20

Germline variants in MAPKAPK3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAPKAPK3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAPKAPK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation	PHASE4	ACTIVE_NOT_RECRUITING
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS	PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPKAPK3 binder may also engage these)

Protein	Name	Similarity
Q66H84	—	1.000	Q66H84 →
Q3SYZ2	—	1.000	Q3SYZ2 →
Q3UMW7	—	1.000	Q3UMW7 →
MAPKAPK2	MAP kinase-activated protein kinase 2	0.989	landscape →
P49138	—	0.987	P49138 →
P49139	—	0.974	P49139 →
Q9FFP9	—	0.966	Q9FFP9 →
Q7XQP4	—	0.965	Q7XQP4 →
Q6ZI44	—	0.963	Q6ZI44 →
A0A8I5ZNK2	—	0.963	A0A8I5ZNK2 →
Q5XIS9	—	0.962	Q5XIS9 →
Q75H77	—	0.962	Q75H77 →
A2YNT8	—	0.961	A2YNT8 →
A2ZAB5	—	0.960	A2ZAB5 →
P0C5D6	—	0.960	P0C5D6 →
Q91604	—	0.960	Q91604 →
AKT1	RAC-alpha serine/threonine-protein kinase	0.959	landscape →
P43292	—	0.959	P43292 →
A9TF79	—	0.959	A9TF79 →
Q9C958	—	0.959	Q9C958 →
Q75V57	—	0.959	Q75V57 →
Q0D4J7	—	0.958	Q0D4J7 →
Q9WTK7	—	0.958	Q9WTK7 →
P97711	—	0.958	P97711 →
Q6P9R2	—	0.957	Q6P9R2 →
PRKD2	Serine/threonine-protein kinase D2	0.957	landscape →
Q7Y0B9	—	0.957	Q7Y0B9 →
P31750	—	0.957	P31750 →
Q5N942	—	0.957	Q5N942 →
STK11	Serine/threonine-protein kinase STK11	0.956	landscape →